The burden loss drug increase is not over but — this is what to anticipate within the 12 months forward

Demand for the medication is unlikely to decelerate in 2024, particularly as therapies steadily change into extra accessible. A lot of Wall Avenue believes the burden loss drug market will solely increase, with some analysts projecting that it will likely be value $100 billion by the top of the last decade. Goldman Sachs analysts anticipate 15 million U.S. adults to be on weight problems drugs by 2030.

However subsequent 12 months, buyers can be watching how the dominant gamers out there, Novo Nordisk and Eli Lilly, navigate provide points plaguing their therapies. Sufferers have been struggling to get their arms on Novo Nordisk’s weight reduction injection Wegovy, its diabetes remedy Ozempic, and Eli Lilly’s diabetes injection Mounjaro.

Analysts anticipate provide constraints to enhance however observe that the broader concern will take years to resolve. 

Exterior of provide headwinds and the shortage of broader insurance coverage protection for weight reduction medication, Novo Nordisk and Eli Lilly have a giant 12 months forward of them. 

Novo Nordisk may win approvals for expanded use of Wegovy within the U.S. and Europe. Eli Lilly’s newly accredited weight reduction drug, Zepbound, may garner greater than a billion {dollars} in gross sales in its first 12 months available on the market.

Each corporations are additionally anticipated to launch new information that would present different potential well being advantages of their medication past weight reduction and diabetes administration, which can improve insurance coverage protection down the road. 

Subsequent 12 months might imply much more to the opposite corporations hoping to hitch what’s to date been a two-horse race to make weight reduction therapies.

New drug information from Pfizer and Amgen, and the potential for extra buyouts or collaborations between bigger corporations and smaller makers of weight problems medication, may alter the market’s aggressive panorama within the coming months.

The provide issues plaguing Wegovy, Ozempic and Mounjaro are seemingly “the largest factor” buyers will watch subsequent 12 months, Guggenheim analyst Seamus Fernandez informed CNBC. 

Some analysts mentioned provide constraints will seemingly persist for years, however anticipate them to ease in 2024 as Novo Nordisk and Eli Lilly work to increase manufacturing capability for his or her medication. 

Novo Nordisk throughout its third-quarter earnings name in November mentioned it’s “taking a look at considerably scaling our provide” of Wegovy within the U.S. in 2024. TD Cowen analyst Michael Nedelcovych informed CNBC that the corporate in the course of the name appeared to counsel that such a change would not seem like a giant bounce in provide however reasonably regular enhancements over time.

Provide may improve extra considerably years from now: Novo Nordisk in November mentioned it could make investments $6 billion to increase its manufacturing services in Denmark, noting it’ll end building from the top of 2025 via 2029. The corporate additionally mentioned it could spend round $2.3 billion to increase one other manufacturing web site in France. 

In the meantime, Eli Lilly mentioned throughout its third-quarter earnings name in November that offer of Mounjaro has improved within the U.S. even because it stays constrained across the globe.

Executives additionally mentioned that Eli Lilly is on monitor to realize its aim of doubling manufacturing capability for medication comparable to Mounjaro, partly via investments in new manufacturing websites in North Carolina and Indiana.

However Eli Lilly CEO David Ricks mentioned on the decision that the corporate is “aggressively planning” additional manufacturing buildup for Mounjaro and different medication. He added that “it is an issue we work on daily. So we’re by no means proud of the capability.”

Morgan Stanley expects Zepbound to rake in $2.2 billion in gross sales in 2024, in keeping with a observe launched after the drug’s approval in November. In the meantime, Financial institution of America analysts in a November observe projected $2.7 billion in Zepbound income in 2024. 

Some analysts anticipate way more gross sales development for Zepbound and Mounjaro past 2024. Tirzepatide, the lively ingredient in each medication, has a “very robust shot of being the best-selling molecule of all time within the pharmaceutical business,” mentioned Guggenheim’s Fernandez. 

Wall Avenue is obsessed with Zepbound partly as a result of it could trigger extra weight reduction than Wegovy. Research instantly evaluating the 2, together with an ongoing trial from Eli Lilly, would want to substantiate that.

Outcomes from that trial may come out subsequent 12 months after preliminary information from separate research inspecting Zepbound as a possible remedy for different well being circumstances, together with coronary heart failure.

Combined insurance coverage protection will seemingly weigh on gross sales of Zepbound and different weight reduction medication in 2024, however Eli Lilly has already secured some protection for the drug. 

Wegovy made historical past this 12 months when it slashed the chance of great coronary heart issues by 20% in individuals with weight problems and coronary heart illness in a late-stage trial. In 2024, the drug may shake up the pharmaceutical business once more if U.S. and European regulators resolve to approve it for that goal. 

These potential approvals, which might make Wegovy the primary GLP-1 drug to have an expanded use for coronary heart well being, are a “foregone conclusion” for Novo Nordisk, Cantor Fitzgerald’s Louise Chen informed CNBC.  

An FDA approval may probably improve the uptake of Wegovy, encouraging extra weight problems specialists, major care suppliers and cardiologists to prescribe it to eligible sufferers, mentioned Dr. Eduardo Grunvald, medical director for UC San Diego’s Middle for Superior Weight Administration.

An approval might also put extra stress on U.S. insurers to finally cowl Wegovy and related weight reduction therapies, opening the door for broader use.

Eli Lilly can be finding out the cardiovascular advantages of Zepbound in a section three medical trial in diabetes sufferers with elevated cardiovascular threat, and outcomes are anticipated in late 2024. The drugmaker is conducting a related examine in overweight sufferers with heart-health dangers, however outcomes might not come till 2027. 

In the meantime, Novo Nordisk’s different therapies may attain their very own milestones subsequent 12 months.

Novo Nordisk expects to launch information within the first half of 2024 from a late-stage trial inspecting Ozempic as a remedy for kidney failure in diabetes sufferers with persistent kidney illness. The corporate hinted that the trial could be successful when it halted the examine a 12 months sooner than deliberate in October primarily based on an interim evaluation.

Novo Nordisk can even launch section three medical trial information on a 25-milligram model of its once-a-day weight reduction capsule, which makes use of semaglutide, the identical lively ingredient as in Ozempic and Wegovy. 

That trial is essential as a result of Novo Nordisk is ready to see that information earlier than submitting for approval of the oral weight reduction drug, mentioned Cowen’s Nedelcovych. He added that in the long run, the provision of weight-loss tablets may enhance capability for his or her injectable counterparts. 

Additionally in 2024, a examine following sufferers from a earlier late-stage trial may probably generate information supporting Wegovy as a remedy for stopping the event of diabetes, Nedelcovych mentioned.

New information subsequent 12 months can be essential to figuring out whether or not Pfizer will get a bit of the burden loss drug area. The stakes are excessive: CEO Albert Bourla has mentioned the corporate hopes to seize $10 billion of that market. 

Pfizer axed a twice-daily model of the one weight problems product in its pipeline earlier this month after sufferers taking the capsule misplaced vital weight however had hassle tolerating the drug in a mid-stage examine. 

Now, the corporate is pinning its hopes on a once-a-day model of the capsule, often known as danuglipron, which it believes might trigger fewer opposed uncomfortable side effects. Pfizer mentioned it expects to launch extra information on that model of the drug within the first half of 2024, which is able to assist the corporate resolve whether or not to start out a late-stage examine on the capsule. 

Nevertheless, some analysts have raised questions on whether or not the once-a-day model can be simpler to tolerate.

“Regardless of ongoing work, tolerability nonetheless seems to be a difficulty with the product, and it isn’t clear to us why this may enhance” in a section three trial or with a once-daily model, JPMorgan analyst Chris Schott mentioned in a December observe.

Barclays analyst Carter Gould mentioned in a December observe that it’s “more and more obvious” that the corporate must look externally for an weight problems remedy, whether or not that is via an acquisition or partnership, to seize a slice of the burden loss drug market prefer it had hoped.

In the meantime, upcoming information will reveal how severe Amgen’s weight reduction drug portfolio is. Within the first half of 2024, Amgen is slated to publish early stage trial information on an oral weight reduction medicine.

Within the second half of the 12 months, Amgen plans to launch mid-stage trial information on an injectable drug that helped trigger as much as 14.5% weight loss after 12 weeks in an early examine.

Pfizer is not the one firm that would profit from trying externally for weight problems medication. 

Bigger drugmakers used acquisitions of smaller companies, or partnerships with them, to carve out area within the weight reduction drug market this 12 months. Extra corporations may deploy the technique subsequent 12 months, analysts mentioned.

“There are a bunch of different large-cap pharmas on the listing who may do that,” mentioned Cantor Fitzgerald’s Chen. 

Swiss firm Roche mentioned earlier this month it could purchase the privately held U.S. weight problems drugmaker Carmot Therapeutics for $2.7 billion. AstraZeneca signed a licensing settlement with Chinese language biotech firm Eccogene to develop an weight problems capsule. 

Novo Nordisk and Eli Lilly have additionally snapped up smaller weight problems drug corporations this 12 months to keep up their dominance out there. 

In an announcement to CNBC, Novo Nordisk mentioned it has elevated its concentrate on “sourcing and elevating exterior innovation” to enhance its in-house merchandise and broaden its drug pipeline, particularly for diabetes, weight problems, heart problems and uncommon blood problems.

The corporate additionally mentioned it’s within the “full vary of enterprise improvement actions,” from acquisitions to partnerships on early or late-stage merchandise, relating to corporations with new organic medication, new potential remedy targets and new mechanisms of motion, or how a drug works.

Chen mentioned acquisitions or partnerships could be the solely means for small- to mid-cap weight reduction drugmakers to meet up with Eli Lilly and Novo Nordisk.

Some smaller corporations have indicated that they’re open to the concept: Altimmune mentioned Dec. 5 that it’s on the lookout for companions to launch and develop its experimental weight problems drug pemvidutide. 

Shares of Altimmune have jumped greater than 140% since Nov. 30, when the corporate launched mid-stage trial information displaying that its injectable drug triggered 15.6% weight reduction on common after 48 weeks.

Different smaller weight reduction drugmakers embrace Construction Therapeutics, whose once-daily capsule helped obese or overweight sufferers lose as much as 10 kilos of weight on common after a month in an early-stage trial. The corporate is anticipated to report mid-stage trial information on its drug in diabetes sufferers this month and extra outcomes on the capsule in sufferers with weight problems early subsequent 12 months, Guggenheim’s Fernandez famous. 

Nonetheless, some larger drugmakers might wait to see bigger and later-stage information from smaller corporations earlier than transferring to accumulate them. That information might not come out till 2025 or later for a lot of corporations, mentioned Fernandez.